These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 30927733)

  • 1. Neurofilament light chain as an indicator of exacerbation prior to clinical symptoms in multiple sclerosis.
    Edwards KR; Garten L; Button J; O'Connor J; Kamath V; Frazier C
    Mult Scler Relat Disord; 2019 Jun; 31():59-61. PubMed ID: 30927733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies.
    Martin SJ; McGlasson S; Hunt D; Overell J
    J Neurol Neurosurg Psychiatry; 2019 Sep; 90(9):1059-1067. PubMed ID: 31123141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome.
    van der Vuurst de Vries RM; Wong YYM; Mescheriakova JY; van Pelt ED; Runia TF; Jafari N; Siepman TA; Melief MJ; Wierenga-Wolf AF; van Luijn MM; Samijn JP; Neuteboom RF; Hintzen RQ
    Mult Scler; 2019 Jun; 25(7):958-967. PubMed ID: 29774770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis.
    Lycke JN; Karlsson JE; Andersen O; Rosengren LE
    J Neurol Neurosurg Psychiatry; 1998 Mar; 64(3):402-4. PubMed ID: 9527161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of CSF neurofilament light and heavy chain protein in MS.
    Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L
    Mult Scler; 2013 Oct; 19(12):1597-603. PubMed ID: 23529999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurofilaments and 10-year follow-up in multiple sclerosis.
    Bhan A; Jacobsen C; Myhr KM; Dalen I; Lode K; Farbu E
    Mult Scler; 2018 Sep; 24(10):1301-1307. PubMed ID: 30066611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis.
    Gaetani L; Salvadori N; Lisetti V; Eusebi P; Mancini A; Gentili L; Borrelli A; Portaccio E; Sarchielli P; Blennow K; Zetterberg H; Parnetti L; Calabresi P; Di Filippo M
    J Neurol; 2019 Sep; 266(9):2157-2163. PubMed ID: 31129709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurofilament light chain in the assessment of patients with multiple sclerosis.
    Domingues RB; Fernandes GBP; Leite FBVM; Senne C
    Arq Neuropsiquiatr; 2019 Jul; 77(6):436-441. PubMed ID: 31314847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
    Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J
    Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis.
    Gaetani L; Eusebi P; Mancini A; Gentili L; Borrelli A; Parnetti L; Calabresi P; Sarchielli P; Blennow K; Zetterberg H; Di Filippo M
    Mult Scler Relat Disord; 2019 Oct; 35():228-232. PubMed ID: 31404762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis.
    McComb M; Krikheli M; Uher T; Browne RW; Srpova B; Oechtering J; Maceski AM; Tyblova M; Jakimovski D; Ramasamy DP; Bergsland N; Krasensky J; Noskova L; Fialova L; Weinstock-Guttman B; Havrdova EK; Vaneckova M; Zivadinov R; Horakova D; Kuhle J; Ramanathan M
    J Clin Lipidol; 2020; 14(5):675-684.e2. PubMed ID: 32758395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and MRI correlates of CSF neurofilament light chain levels in relapsing and progressive MS.
    Damasceno A; Dias-Carneiro RPC; Moraes AS; Boldrini VO; Quintiliano RPS; da Silva VAPG; Farias AS; Brandão CO; Damasceno BP; Dos Santos LMB; Cendes F
    Mult Scler Relat Disord; 2019 May; 30():149-153. PubMed ID: 30772673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can CSF biomarkers predict future MS disease activity and severity?
    Magliozzi R; Cross AH
    Mult Scler; 2020 Apr; 26(5):582-590. PubMed ID: 31965889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis.
    Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
    J Neuroinflammation; 2018 Jul; 15(1):209. PubMed ID: 30021640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurofilament and glial fibrillary acidic protein in multiple sclerosis.
    Norgren N; Sundström P; Svenningsson A; Rosengren L; Stigbrand T; Gunnarsson M
    Neurology; 2004 Nov; 63(9):1586-90. PubMed ID: 15534240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis.
    Villar LM; Picón C; Costa-Frossard L; Alenda R; García-Caldentey J; Espiño M; Muriel A; Álvarez-Cermeño JC
    Eur J Neurol; 2015 Aug; 22(8):1169-75. PubMed ID: 25324032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS.
    Thebault S; R Tessier D; Lee H; Bowman M; Bar-Or A; Arnold DL; L Atkins H; Tabard-Cossa V; Freedman MS
    Neurol Neuroimmunol Neuroinflamm; 2019 Sep; 6(5):e598. PubMed ID: 31516913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased cerebrospinal fluid neurofilament light chain in central nervous system inflammatory demyelinating disease.
    Peng L; Bi C; Xia D; Mao L; Qian H
    Mult Scler Relat Disord; 2019 May; 30():123-128. PubMed ID: 30771578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal Fluid Neurofilament Light Chain Is Associated with Kynurenine Pathway Metabolite Changes in Multiple Sclerosis.
    Rajda C; Galla Z; Polyák H; Maróti Z; Babarczy K; Pukoli D; Vécsei L
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32290514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.
    Sellebjerg F; Royen L; Soelberg Sørensen P; Oturai AB; Jensen PEH
    Mult Scler; 2019 Oct; 25(11):1444-1451. PubMed ID: 30113249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.